Physician profile
Vincent K Lam
NPI 1265758601
$80,351.61
in general payments reported to CMS, 2019-2025
21 companies · $8,656 in 2025
The $8,656 reported for 2025 was more than what 79% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,442 · 2020: $7,275 · 2021: $6,815 · 2022: $7,298 · 2023: $3,046 · 2024: $39K · 2025: $8,656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $30K · Travel and Lodging: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,460 · Food and Beverage: $1,531 · Education: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $30,231.20 |
| Travel and Lodging | $11,450.08 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,460.00 |
| Food and Beverage | $1,530.78 |
| Education | $850.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $26,081.36 | 2020-2024 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $18,550.00 | 2019-2024 | Alunbrig |
| Genentech USA, INC. | $8,886.61 | 2024 | Alecensa |
| Eli Lilly and Company | $4,474.69 | 2019-2025 | |
| Pfizer INC. | $4,110.05 | 2024-2025 | |
| Roche Molecular Systems, INC. | $3,863.28 | 2025 | |
| Gilead Sciences, INC. | $3,418.07 | 2024 | |
| Seagen INC. | $2,925.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $2,851.91 | 2021-2025 | |
| Daiichi Sankyo INC. | $1,740.50 | 2022-2025 | |
| Glaxosmithkline, LLC. | $1,325.83 | 2019 | |
| Merck Sharp & Dohme LLC | $1,000.00 | 2023 | |
| Novocure INC. | $685.00 | 2022 | |
| Caris Mpi, INC. | $104.51 | 2025 | Mi Cancer Seek |
| Jazz Pharmaceuticals INC. | $103.80 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $100.07 | 2019 | |
| Genentech, INC. | $76.27 | 2025 | Tecentriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.40 | 2019 | |
| Amgen INC. | $19.26 | 2024 | Tepezza |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.